• 1038 Citations
  • 18 Scopus h-Index
20052019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Sikander Ailawadhi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 30 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma

Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M. H., Posner, G., Ralston, S., Zagadailov, E., Ba-Mancini, A. & Rifkin, R., Jan 1 2019, In : Clinical therapeutics.

Research output: Contribution to journalArticle

  • 1 Scopus citations

    Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

    Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan Khan, A. A., Ruehle, M., Rharbaoui, F., Haeder, T., Wartenberg-Demand, A. & Anderson, K. C., Jan 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia.

    Research output: Contribution to journalArticle

  • 5 Scopus citations

    Influence of Sociodemographic Factors on Treatment Decisions in Non–Small-Cell Lung Cancer

    Duma, N., Idossa, D. W., Durani, U., Frank, R. D., Paludo, J., Westin, G., Lou, Y., Mansfield, A. S., Adjei, A. A., Go, R. S. & Ailawadhi, S., Jan 1 2019, (Accepted/In press) In : Clinical Lung Cancer.

    Research output: Contribution to journalArticle

  • Monoclonal antibody utilization characteristics in patients with multiple myeloma

    Ailawadhi, S., Sher, T., Azzouqa, A. G., Meghji, Z., Jain, T., Jani, P., Ahmed, S., Diehl, N., Roy, V., Shah, V., Hodge, D., Ailawadhi, M., Alegria, V. R., Paulus, A., Chanan Khan, A. A. & Fonseca, R., Sep 1 2019, In : Anti-cancer drugs. 30, 8, p. 859-865 7 p.

    Research output: Contribution to journalArticle

  • Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

    Siddiqi, T., Frankel, P., Beumer, J. H., Kiesel, B. F., Christner, S., Ruel, C., Song, J. Y., Chen, R., Kelly, K. R., Ailawadhi, S., Kaesberg, P., Popplewell, L., Puverel, S., Piekarz, R., Forman, S. J. & Newman, E. M., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

    Research output: Contribution to journalArticle